Daily FNArena News - FYI

Peter Switzer of the Switzer Report selects two stocks which suggest the trend is your friend.

Pitt Street Research analyst Stuart Roberts speaks with Scott Brown, MD of Real Energy

Peter Switzer of the Switzer Report suggests ten stocks (including ETFs) that he sees as trade deal beneficiaries.

Pitt Street Research initiates coverage of China-based eLearning SaaS company, Retech Technology.

The New Criterion’s Tim Boreham notes massive legal settlements in the US have highlighted the scourge of opioid abuse, but Australian producer Palla Pharma is confident the drug class will remain the world’s foremost pain medication.

Pitt Street Research has revised its valuation range for MyFiziq.

Peter Switzer of the Switzer Super Report suggests gold’s run is over and its time to back the stock market.

Pitt Street Research has initiated coverage of Sydney-based Energy Technologies, an emerging cable and wire player.

Pitt Street Research explains why Imagion Biosystems shares look undervalued.

Peter Switzer of the Switzer Super Report applies the “Buffett test” to the value of Link Administration.